Researchers have discovered that a drug named niraparib, can prove beneficial for women newly diagnosed with advanced ovarian cancer.The study demonstrates that administering niraparib after conventional chemotherapy treatment in newly diagnosed patients, improves their progression-free survival, and reduces their risk of relapse or death from this disease.The study published in New England Journal of Medicine shows that administering niraparib reduces risk of relapse or death from this disease by nearly 40 per cent."We evaluated the benefits of using niraparib after standard treatment of ovarian cancer based on chemotherapy after surgery. With this new therapeutic approach we have observed a significant improvement in patient progression-free survival and a reduction of almost 40 per cent of their risk of relapse," said first author Dr Antonio Gonzalez Martin, Clinica Universidad Navarra and president of the Spanish Ovarian Cancer Research group.Ovarian cancer, diagnosed in around ...
